title: [Percutaneous neurolysis of the celiac plexus under CT guidance in the invasive treatment of visceral pain caused by cancer].
abstract: To verify the effectiveness and the incidence of complication in the transcutaneal celiac plexus block with CT-guided in the patient with intractable upper abdominal cancer, using alcoholic solutions to different concentrations (50% and 96%), previous insertion of the peridural catheter. From December 1997 to June 2002, studies were carried out on 24 patients with CT-guided percutaneous coeliac plexus neurolysis including 17 men and 7 women with inoperable abdominal malignancy and two with chronic pancreatitis. The patients were affected by very intense pain controllable only with high doses of analgesic narcotics. Before the procedure a catheter was installed in the peridurale space between L1-T12. To avoid general anesthesia, 40 mL of marcaine 0.5% was injected to relieve the back pain sometimes reported after the neurolysis, caused by the diffusion of alcohol in the coeliac plexus. This technique requires a posterior percutaneous procedural transaortic approach CT scan guided, to determine the correct position of the needle tips and the spread of neurolytic solution (40 mL of 96% + 3 mL of contrast medium) around the origin of the coeliac trunk's anatomical center of the plexus. The first 10 patients have received 40 mL of 50% ethyl alcohol + 3 mL of contrast medium. To evaluate the rate of the analgesia relief, a visual analogue pain score (VAS) was used before and 48 hours after the neurolysis. The percutaneous neurolysis of the celiac plexus is useful to relieve the pain in patients affected by cancer developing in upper abdomen. The CT-scan guide of the needle allows an omogeneous distribution of the contrast medium. The insertion of the peridural catheter made a complete analgesia and reduced the incidence of complications. Our method provided an excellent control of the pain in all patients. In our experience the pain relief was almost complete in patients treated with 96% ethyl alcohol solution (VAS from 8 before the treatment to 1, 48 hours after the treatment). The alcohol administered in elevated concentrations (96%), does not increase the incidence of complications.
authors.affiliation: Servizio di Radiodiagnostica, Ospedale Oncologico A Businco, ASL 8, UO Terapia Antalgica.
authors.forename: C
authors.initials: C
authors.lastname: Pusceddu
authors.forename: S
authors.initials: S
authors.lastname: Mameli
authors.forename: A
authors.initials: A
authors.lastname: Pili
authors.forename: G
authors.initials: G
authors.lastname: Podda
mesh_terms: D000008:Abdominal Neoplasms / Q000503:physiopathology*; D000328:Adult; D000368:Aged; D015360:Analgesia, Epidural; D001340:Autonomic Nerve Block / Q000009:adverse effects / Q000379:methods*; D001416:Back Pain / Q000188:drug therapy; D002045:Bupivacaine; D002447:Celiac Plexus / Q000000981:diagnostic imaging; D002908:Chronic Disease; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010148:Intractable Pain / Q000209:etiology / Q000628:therapy*; D010195:Pancreatitis / Q000503:physiopathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014781:Viscera / Q000294:innervation
chemical_list: D000431:Ethanol; D002045:Bupivacaine